Potential safety issues have prompted Forest Laboratories and its development partner, Germany's Paion, to halt enrolling patients in a late-stage trial of a compound that mimics a protein found in bat saliva. The independent monitoring committee says they want time to analyze more of the data from the drug, desmoteplase, to evaluate a "safety signal." No other details were provided. Desmoteplase is a clot-dissolving protein intended as a treatment for stroke.
- see the release on the trial